Source:http://linkedlifedata.com/resource/pubmed/id/16797400
Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
1
|
pubmed:dateCreated |
2006-6-26
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical | |
pubmed:status |
MEDLINE
|
pubmed:month |
Jul
|
pubmed:issn |
1523-6838
|
pubmed:author | |
pubmed:issnType |
Electronic
|
pubmed:volume |
48
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
159-66
|
pubmed:dateRevised |
2007-11-15
|
pubmed:meshHeading |
pubmed-meshheading:16797400-Biological Markers,
pubmed-meshheading:16797400-Clinical Trials as Topic,
pubmed-meshheading:16797400-Drug Approval,
pubmed-meshheading:16797400-Endpoint Determination,
pubmed-meshheading:16797400-Humans,
pubmed-meshheading:16797400-Internal Medicine,
pubmed-meshheading:16797400-Nephrology,
pubmed-meshheading:16797400-Outcome Assessment (Health Care)
|
pubmed:year |
2006
|
pubmed:articleTitle |
Surrogate markers in clinical studies: problems solved or created?
|
pubmed:publicationType |
Editorial
|